what could go wrong?, page-66

I'm really just using some commons sense here...

Do we even know for certain that the study is still running?

Also, just because the study extends on for months, it doesn't translate into median PFS extending by months aswell- Over the course of the study there will likely of been patients from both arms who have been slow to progress, and patients from both arms who have progressed much faster- so we're looking at the difference between the middle of each arm.

The trial was never going to report until 2014, and now appears to have gone on a few months past what was expected. This could suggest PFS in either arm has improved by more than what was anticipated, or from what's been observed in other similar 2nd line cohorts. Although as pointed out awhile back by Andrew, you can't go making judgements between different cohorts. So we can't be sure that All patients potentially left on the study are from the HA arm alone.

I think all anyone can say at this stage is that since the trial has extended on longer than expected( perhaps by the company's expectations, and by some data modelling presented by tewkle/ ViperX1) Then things look encouraging considering the improvements HA-irinotecan has demonstrated over irinotecan in the Phase 2 study.